Portsmouth, NH, United States of America

Argeris N Karabelas

USPTO Granted Patents = 1 

 

 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2017

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Argeris N. Karabelas in Treating Schizophrenia

Introduction

Argeris N. Karabelas, based in Portsmouth, NH, is an innovative inventor recognized for his contributions to the field of neuroscience. With a focus on mental health, specifically schizophrenia, his work has paved the way for new treatment methodologies that can significantly impact patients’ lives.

Latest Patents

Dr. Karabelas holds a patent for "Methods of use of cyclic amide derivatives to treat schizophrenia." This patent details compositions and methods designed to address both the positive and negative symptoms associated with schizophrenia, marking a notable advancement in therapeutic options for this complex mental disorder.

Career Highlights

Over his career, Argeris has worked with notable companies in the pharmaceutical industry, including Minerva Neurosciences, Inc. and Cyrenaic Pharmaceuticals, Inc. His expertise in neuroscience and pharmacology has played a critical role in developing new treatments aimed at improving patient health and well-being.

Collaborations

Throughout his professional journey, Argeris has collaborated with eminent colleagues such as Remy Henri Luthringer and Lorenzo Pellegrini. These partnerships have fostered an environment of innovation, combining expertise from various facets of research to enhance the understanding and treatment of schizophrenia.

Conclusion

Argeris N. Karabelas stands out as an influential figure in the realm of neuroscience. His patented methods represent a significant leap forward in psychiatric treatment, showcasing the vital role of inventors in transforming innovative ideas into real-world applications that can improve mental health for countless individuals.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…